Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

Cancer Cell

Volumn 19, Issue 5, 2011, Pages 575-586

  Carver, Brett S ^a   Chapinski, Caren ^a   Wongvipat, John ^a   Hieronymus, Haley ^a   Chen, Yu ^a   Chandarlapaty, Sarat ^a   Arora, Vivek K ^a   Le, Carl ^a   Koutcher, Jason ^a   Scher, Howard ^a   Scardino, Peter T ^a   Rosen, Neal ^a   Sawyers, Charles L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; FEEDBACK SYSTEM; HUMAN; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; XENOGRAFT;

MURINAE;

EID: 79955975429     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.04.008     Document Type: Article

References (46)

1. Cancer Facts and Figures 2010 2010, American Cancer Society, American Cancer Society, Atlanta.
2. Brachmann S.M., Hofmann I., Schnell C., Fritsch C., Wee S., Lane H., Wang S., Garcia-Echeverria C., Maira S.M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA 2009, 106:22299-22304.
3. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
4. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
5. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
6. Chen M.L., Xu P.Z., Peng X.D., Chen W.S., Guzman G., Yang X., Di Cristofano A., Pandolfi P.P., Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 2006, 20:1569-1574.
7. Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., Vincent J.P., Ellston R., Jones D., Sini P., et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010, 70:288-298.
8. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28:1075-1083.
9. Craft N., Chhor C., Tran C., Belldegrun A., DeKernion J., Witte O.N., Said J., Reiter R.E., Sawyers C.L. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999, 59:5030-5036.
10. Creighton C.J. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PloS One 2008, 3:e1816.
11. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V., Sawyers C.L. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4:223-238.
12. El Sheikh S.S., Romanska H.M., Abel P., Domin J., Lalani el-N. Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer-a pilot study. Neoplasia 2008, 10:949-953.
13. Gao T., Furnari F., Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 2005, 18:13-24.
14. Gao H., Ouyang X., Banach-Petrosky W.A., Shen M.M., Abate-Shen C. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res. 2006, 66:7929-7933.
15. Guertin D.A., Stevens D.M., Saitoh M., Kinkel S., Crosby K., Sheen J.H., Mullholland D.J., Magnuson M.A., Wu H., Sabatini D.M. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009, 15:148-159.
16. Ham W.S., Cho N.H., Kim W.T., Ju H.J., Lee J.S., Choi Y.D. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy. J. Urol. 2009, 182:1378-1384.
17. Hieronymus H., Lamb J., Ross K.N., Peng X.P., Clement C., Rodina A., Nieto M., Du J., Stegmaier K., Raj S.M., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10:321-330.
18. Jiao J., Wang S., Qiao R., Vivanco I., Watson P.A., Sawyers C.L., Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res. 2007, 67:6083-6091.
19. Kinkade C.W., Castillo-Martin M., Puzio-Kuter A., Yan J., Foster T.H., Gao H., Sun Y., Ouyang X., Gerald W.L., Cordon-Cardo C., Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 2008, 118:3051-3064.
20. Lin H.K., Hu Y.C., Yang L., Altuwaijri S., Chen Y.T., Kang H.Y., Chang C. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J. Biol. Chem. 2003, 278:50902-50907.
21. Lin H.K., Hu Y.C., Lee D.K., Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol. Endocrinol. 2004, 18:2409-2423.
22. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
23. Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L., Earp H.S., Whang Y.E. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc. Natl. Acad. Sci. USA 2007, 104:8438-8443.
24. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10:594-601.
25. Mellinghoff I.K., Vivanco I., Kwon A., Tran C., Wongvipat J., Sawyers C.L. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004, 6:517-527.
26. Nardella C., Carracedo A., Alimonti A., Hobbs R.M., Clohessy J.G., Chen Z., Egia A., Fornari A., Fiorentino M., Loda M., et al. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci. Signal. 2009, 2:ra2.
27. Nelson P.S., Clegg N., Arnold H., Ferguson C., Bonham M., White J., Hood L., Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl. Acad. Sci. USA 2002, 99:11890-11895.
28. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
29. Pei H., Li L., Fridley B.L., Jenkins G.D., Kalari K.R., Lingle W., Petersen G., Lou Z., Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009, 16:259-266.
30. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351:1513-1520.
31. Reid A.H., Attard G., Ambroisine L., Fisher G., Kovacs G., Brewer D., Clark J., Flohr P., Edwards S., Berney D.M., et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer 2010, 102:678-684.
32. Rini B.I., Small E.J. Hormone-refractory prostate cancer. Curr. Treat. Options Oncol. 2002, 3:437-446.
33. Saal L.H., Johansson P., Holm K., Gruvberger-Saal S.K., She Q.B., Maurer M., Koujak S., Ferrando A.A., Malmstrom P., Memeo L., et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl. Acad. Sci. USA 2007, 104:7564-7569.
34. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
35. Schulman C.C., Debruyne F.M., Forster G., Selvaggi F.P., Zlotta A.R., Witjes W.P. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 2000, 38:706-713.
36. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
37. Singh P., Yam M., Russell P.J., Khatri A. Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett. 2010, 293:1-14.
38. Solit D.B., Rosen N. Targeting HER2 in prostate cancer: where to next?. J. Clin. Oncol. 2007, 25:241-243.
39. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
40. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284:8023-8032.
41. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., Wongvipat J., Smith-Jones P.M., Yoo D., Kwon A., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
42. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003, 1:E59.
43. Wang Y., Mikhailova M., Bose S., Pan C.X., deVere White R.W., Ghosh P.M. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008, 27:7106-7117.
44. Yao E., Zhou W., Lee-Hoeflich S.T., Truong T., Haverty P.M., Eastham-Anderson J., Lewin-Koh N., Gunter B., Belvin M., Murray L.J., et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin. Cancer Res. 2009, 15:4147-4156.
45. Yeh S., Lin H.K., Kang H.Y., Thin T.H., Lin M.F., Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 1999, 96:5458-5463.
46. Zhang W., Zhu J., Efferson C.L., Ware C., Tammam J., Angagaw M., Laskey J., Bettano K.A., Kasibhatla S., Reilly J.F., et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res. 2009, 69:7466-7472.